Sonoma Pharmaceuticals (SNOA) Cost of Revenue (2010 - 2026)

Sonoma Pharmaceuticals' Cost of Revenue history runs 17 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 51.84% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 37.3% increase from a year earlier, with the FY2026 full-year figure at $12.1 million, up 37.3% from the prior year.
• Cost of Revenue climbed to $3.4 million in Q1 2026 per SNOA's latest filing, from $2.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $3.5 million in Q3 2025 and bottomed at $1.7 million in Q4 2023.
• The 5-year median for Cost of Revenue is $2.2 million (2023), against an average of $2.3 million.
• Across the five-year window, Cost of Revenue slipped 28.29% in 2022 and surged 57.08% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $2.1 million in 2022, then retreated by 20.59% to $1.7 million in 2023, then soared by 36.71% to $2.3 million in 2024, then climbed by 17.65% to $2.7 million in 2025, then rose by 25.23% to $3.4 million in 2026.
• Per Business Quant, the three latest SNOA Cost of Revenue figures stand at $3.4 million (Q1 2026), $2.7 million (Q4 2025), and $3.5 million (Q3 2025).